Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
Part of Heart & circulation clinical trials.
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hypertrophic cardiomyopathy (a thickened heart muscle).
- Your type is non-obstructive (the thickened muscle doesn't block blood flow).
- You have symptoms like shortness of breath or chest discomfort with activity (NYHA class II or III).
- You are able to do an exercise test on a treadmill or bike.
- Your symptoms are not mainly caused by another condition (like lung disease or severe anemia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine called CRD-4730 (taken as a pill) to see if it can improve heart function and symptoms in people with heart failure and a reduced pumping ability. It may help you feel better and slow the progression of your condition.
This trial tests an investigational drug given as an injection under the skin for people with a type of hypertrophic cardiomyopathy that does not block blood flow out of the heart. The goal is to see if the drug is safe and may help improve symptoms.
This trial tests a new drug called HRS-1893 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug can improve symptoms and quality of life.
This trial tests a new medication called baxdrostat that may help reduce thickening of the heart's main pumping chamber (left ventricular hypertrophy), which is often caused by high blood pressure. The study will see if this drug helps improve heart health in people with this condition.
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
This study tests a new medicine called NT-88, which may help improve heart function in people with mild heart failure. It focuses on those with a slightly reduced pumping ability (LVEF 41-49%) and aims to see if the drug is safe and helpful.
Hear when a new Non-obstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.